Scottish venture capital firm Par Equity has sold its stake in medical technology firm PathXL to Philips for an undisclosed sum.
Par Equity said the sale of a reported seven-figure stake taken in 2012 has generated a 270 per cent tax-free return for investors.
Read more at http://www.dailyrecord.co.uk/business/business-science-technology/par-equity-report-270-return-8395358#dQWMwEYsYB5wPq91.99
